Microbiology and Immunology

You are here

Home > Publications > Publications

Publications

Found 139 results
Author Title Type [ Year(Desc)]
Filters: First Letter Of Last Name is J  [Clear All Filters]
2025
Johnson WC, Alivisatos A, Smith TC, Van N, Soni V, Wallach JB, Clark NA, Fitzgerald TA, Whiteley JJ, Tan S et al..  2025.  Integration of multi-modal measurements identifies critical mechanisms of tuberculosis drug action.. Cell Syst. :101348.
Liu Q, Engelhart CA, Wallach JB, Tiwari D, Ge P, Manna A, Panda S, McCue WM, Wong T-Y, Sharma S et al..  2025.  Metabolically Stable Adenylation Inhibitors of Biotin Protein Ligase as Antibacterial Agents.. J Med Chem. 68(3):3065-3087.
Jinich A, Zaveri A, DeJesus MA, Spencer A, Almada-Monter R, Flores-Bautista E, Smith CM, Sassetti CM, Rock JM, Ehrt S et al..  2025.  The Mycobacterium tuberculosis Transposon Sequencing Database (MtbTnDB): A Large-Scale Guide to Genetic Conditional Essentiality.. Mol Microbiol. 124(1):91-101.
Caniels TG, Prabhakaran M, Ozorowski G, MacPhee KJ, Wu W, van der Straten K, Agrawal S, Derking R, Reiss EIMM, Millard K et al..  2025.  Precise targeting of HIV broadly neutralizing antibody precursors in humans.. Science. 389(6759):eadv5572.
Kent A, Mon KJoy Yee, Hutchins Z, Putzel G, Zhigarev D, Grier A, Jia B, Kortlever RM, Barbet G, Evan GI et al..  2025.  A stromal inflammasome Ras safeguard against Myc-driven lymphomagenesis.. Nat Immunol. 26(1):53-67.
Krieger IV, Sukheja P, Yang B, Tang S, Selle D, Woods A, Engelhart C, Kumar P, Harbut MB, Liu D et al..  2025.  SuFEx-based antitubercular compound irreversibly inhibits Pks13.. Nature.
Krieger IV, Sukheja P, Yang B, Tang S, Selle D, Woods A, Engelhart C, Kumar P, Harbut MB, Liu D et al..  2025.  SuFEx-based antitubercular compound irreversibly inhibits Pks13.. Nature.
Schwer B, Prucker I, Sanchez AM, Babor J, Jessen HJ, Shuman S.  2025.  Tandem inactivation of inositol pyrophosphatases Asp1, Siw14, and Aps1 illuminates functional redundancies in inositol pyrophosphate catabolism in fission yeast.. mBio. 16(5):e0038925.
Itkin T, Houghton S, Schreiner R, Lin Y, Badwe CR, Voisin V, Murison A, Seyedhassantehrani N, Kaufmann KB, Garcia-Prat L et al..  2025.  Transcriptional activation of regenerative hematopoiesis via microenvironmental sensing.. Nat Immunol. 26(3):378-390.
2026
Seshadri C, Flynn JAL, Maiello P, Schnappinger D, Wilkinson RJ, Gordon SB, Mwandumba HC, Jambo KC, Hoft DF, Rubin EJ et al..  2026.  Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials.. Lancet Microbe. :101278.
Seshadri C, Flynn JAL, Maiello P, Schnappinger D, Wilkinson RJ, Gordon SB, Mwandumba HC, Jambo KC, Hoft DF, Rubin EJ et al..  2026.  Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials.. Lancet Microbe. :101278.
Warrier T, Martinez-Hoyos M, de Francisco EPorras, Lenaerts AJ, Gruppo V, Robertson GT, Li K, Aubé J, Bonnet I, Jiang X et al..  2026.  Diaryl-Aminoindazole with Extensive In Vitro Mycobactericidal Activity Dependent on Exposure to Reactive Nitrogen Species.. ACS Infect Dis.
Klevorn T, Brown C, Hardy CD, Cuthbert BJ, Spencer A, Jinich A, Chan L, Angala SK, Manzer J, Mendoza J et al..  2026.  A periplasmic protein complex mediates arabinofuranosyltransferase activity and intrinsic drug resistance in Mycobacterium tuberculosis.. Sci Adv. 12(14):eaec5100.
Klevorn T, Brown C, Hardy CD, Cuthbert BJ, Spencer A, Jinich A, Chan L, Angala SK, Manzer J, Mendoza J et al..  2026.  A periplasmic protein complex mediates arabinofuranosyltransferase activity and intrinsic drug resistance in Mycobacterium tuberculosis.. Sci Adv. 12(14):eaec5100.